Skip to main content
Caplight Logo









AmacaThera

AmacaThera

Private
TorontoHealthcare & Life Scienceshttps://amacathera.com/

Last Round

Series A

Extension

Nov 28, 2023

Total Funding Raised

$14.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AmacaThera is a biotechnology company that develops an injectable hydrogel platform for localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

injectable hydrogeldrug deliverysustained releasebiotechnologybiocompatible hydrogeltissue regenerationpost-surgical paindrug delivery platformbiotech licensingdrug delivery techbiomaterialstherapeutic deliverylocalized deliveryhydrogel techpreclinical testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AmacaThera Comparables

Compare AmacaThera with similar companies based on industry and business-model similarity.

AmacaThera comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Allay Therapeutics
88%
AiViva BioPharma
84%
InSitu Biologics, Inc.
83%

AmacaThera Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionNov 28, 2023
Series AFeb 22, 2021
SeedOct 3, 2019

AmacaThera Investors

Notable investors and investment history

AmacaThera investors
InvestorRounds
Grey Sky Venture PartnersSeed
InvereadySeries A, Series A Extension
MaRS Discovery DistrictSeries A, Series A Extension
BDC CapitalSeries A, Series A Extension
Viva BioInnovatorSeries A
Viva BiotechSeed
Lumira VenturesSeed, Series A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 2315% MoM, reaching 3.7K.

  • Jun 26, 2026

    Grew 27% QoQ from 15 to 19 employees.

AmacaThera Filings

Explore SEC and related filing metadata, where available.

AmacaThera filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AmacaThera's valuation, stock price, and market status.

Is AmacaThera a public or private company?

AmacaThera is a private company.

What is the current stock price of AmacaThera?

AmacaThera is a private company with no public stock price. No recent secondary market data is available.

How much is AmacaThera worth (valuation)?

Valuation information for AmacaThera is not publicly available.

Can I buy AmacaThera stock?

AmacaThera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AmacaThera's last funding round?

AmacaThera's most recent funding round was Series A Extension on November 28, 2023.

Who are the main investors in AmacaThera?

Key investors in AmacaThera include Viva Biotech, Lumira Ventures, Sprout BioVentures.

Will AmacaThera IPO soon?

No public IPO plans have been announced for AmacaThera.

How can I track AmacaThera secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AmacaThera's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersToronto
Employee Range17
Year Founded2016
Last FundingNov 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?